iCAD, Inc. (ICAD)

Market Cap	56.40M
Revenue (ttm)	19.61M
Net Income (ttm)	-5.62M
Shares Out	26.35M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210,847
Open	2.120
Previous Close	2.140
Day's Range	2.030 - 2.160
52-Week Range	1.180 - 3.780
Beta	1.96
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 19, 2025

About ICAD

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 3, 1986
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: ICAD
• Website: https://www.icadmed.com

Financial Performance

In 2024, iCAD, Inc.'s revenue was $19.61 million, an increase of 13.22% compared to the previous year's $17.32 million. Losses were -$5.62 million, 15.9% more than in 2023.